Fight For HIV
As part of our corporate social initiative, Neo-Health has partnered with a well known US corporate to offer free HIV combo testing for NGOs in Hong Kong
The first cases of HIV and AIDS were reported in Hong Kong in 1984 and 1985 respectively. The current trend shows that while transmission among heterosexuals remains stable, infections among local men who have sex with men (MSM) have been increasing.
A total of 725 additional cases of Human Immunodeficiency Virus (HIV) infection were reported to the Center for Health Protection (CHP) of the Department of Health (DH) in 2015, compared with 651 in 2014. Of the 725 newly reported cases, 434 acquired the infection via homosexual or bisexual contact, 135 through heterosexual contact, 14 through drug injection and two by perinatal transmission.
In a bid to raise HIV awareness to stop the rising trend of HIV in Hong Kong, a well known US corporate has partnered with Neo-Health to sponsor free HIV combo tests for local NGOs.
Neo-Health has also partnered with other corporate to offer unique and comprehensive sexual health screening plans specially customized to their budget to encourage sexual health screening for their employees.
With our in-house laboratory that offers innovative, state-of-the-art technology, Neo-Health offers fast, accurate and effective screening tests to cover a comprehensive panel of sexually transmitted diseases.
If you or your company would like to find out more about our sexual health screening plans, do give us a call to discuss more. We would be glad to customize a plan suited for your needs and your budget.
Gardasil 9 has just arrived in Hong Kong!
The latest HPV vaccine includes the greatest number of HPV types in any available HPV vaccine. Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
Seven HPV types covered in Gardasil 9 (HPV 16, 18, 31, 33, 45, 52 and 58) cause approximately 90-95 percent of HPV-related anal cancers, approximately 90 percent of cervical cancers, and approximately 80 percent of high-grade cervical lesions (cervical precancers, defined as CIN 2 and CIN 3) worldwide. These seven HPV types also cause 90 percent of HPV-related vulvar cancers and 85 percent of HPV-related vaginal cancers. HPV types 6 and 11 cause approximately 90 percent of genital warts cases in males and females.
In males, Gardasil 9 helps in the prevention of anal cancer precancerous or dysplastic lesions, and genital warts caused by HPV types 6 and 11.
In females, Gardasil 9 helps in the prevention of cervical, vulvar, vaginal, and anal cancers, precancerous or dysplastic lesions and genital warts.